Machine Learning-Engineered Nanozyme System for Synergistic Anti-Tumor Ferroptosis/Apoptosis Therapy.

Journal: Small (Weinheim an der Bergstrasse, Germany)
PMID:

Abstract

Nanozymes with multienzyme-like activity have sparked significant interest in anti-tumor therapy via responding to the tumor microenvironment (TME). However, the consequent induction of protective autophagy substantially compromises the therapeutic efficacy. Here, a targeted nanozyme system (Fe-Arg-CDs@ZIF-8/HAD, FZH) is shown, which enhances synergistic anti-tumor ferroptosis/apoptosis therapy by leveraging machine learning (ML). A novel ML model, termed the sequential backward Tree-Classifier for Gaussian Process Regression (TCGPR), is proposed to improve data pattern recognition following the divide-and-conquer principle. Based on this, a Bayesian optimization algorithm is employed to select candidates from the extensive search space. Leveraging this fresh material discovery framework, a novel strategy for enhancing nanozyme-based tumor therapy, has been developed. The results reveal that FZH effectively exerts anti-tumor effects by sequentially responding to the TME, having a cascade reaction to induce ferroptosis. Moreover, the endogenous elevation of high concentration nitric oxide (NO) serves as a direct mechanism for killing tumor cells while concurrently suppressing the protective autophagy induced by oxidative stress (OS), enhancing synergistic ferroptosis/apoptosis therapy. Overall, a novel strategy for improving nanozyme-based tumor therapy has been proposed, underlying the integration of ML, experiments, and biological applications.

Authors

  • Tianliang Li
    Department of Biomedical Engineering, National University of Singapore, 21 Lower Kent Ridge Road, Singapore, 119077, Singapore.
  • Bin Cao
    Guangzhou Municipal Key Laboratory of Materials Informatics, Sustainable Energy and Environment Thrust, Advanced Materials Thrust, Hong Kong University of Science and Technology (Guangzhou), Guangzhou, Guangdong, 511400, China.
  • Tianhao Su
    Materials Genome Institute, Shanghai Engineering Research Center for Integrated Circuits and Advanced Display Materials, and Shanghai Engineering Research Center of Organ Repair, Shanghai University, Shanghai, 200444, China.
  • Lixing Lin
    Materials Genome Institute, Shanghai Engineering Research Center for Integrated Circuits and Advanced Display Materials, and Shanghai Engineering Research Center of Organ Repair, Shanghai University, Shanghai, 200444, China.
  • Dong Wang
    Department of Neurosurgery, Tianjin Medical University General Hospital, Tianjin, China.
  • Xinting Liu
    Institute of Genomic Medicine, Wenzhou Medical University, Wenzhou 325035, China.
  • Haoyu Wan
    Materials Genome Institute, Shanghai Engineering Research Center for Integrated Circuits and Advanced Display Materials, and Shanghai Engineering Research Center of Organ Repair, Shanghai University, Shanghai, 200444, China.
  • Haiwei Ji
    Nantong Key Laboratory of Public Health and Medical Analysis, School of Public Health, Nantong University, Nantong, Jiangsu, 226019, PR China. Electronic address: jihaiwei64@ntu.edu.cn.
  • Zixuan He
    National Clinical Research Center for Digestive Diseases, Department of Gastroenterology, Changhai Hospital, Naval Medical University, Shanghai, 200433, China.
  • Yingying Chen
  • Lingyan Feng
    Materials Genome Institute, Shanghai Engineering Research Center for Integrated Circuits and Advanced Display Materials, and Shanghai Engineering Research Center of Organ Repair, Shanghai University, Shanghai, 200444, China.
  • Tong-Yi Zhang
    Materials Genome Institute, Shanghai Engineering Research Center for Integrated Circuits and Advanced Display Materials, and Shanghai Engineering Research Center of Organ Repair, Shanghai University, Shanghai, 200444, China.